Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction

NCT03036124 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03036124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03036124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 8, 2017
Completion date
July 17, 2019
Enrollment
4,744 (actual)
Sites
419

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with reduced ejection fraction (hfref)